Tech Seeker (TS)

Progenics Pharmaceuticals Inc (AKA:Progenics Inc)
Profile last edited on: 4/4/2022

Radiopharmaceuticals and molecular imaging diagnostics for prostate cancer
TS Type
Small Corporation
Status
Inactive
Year Founded
1986
Last Involved Year
2013

Key People / Management

  John Babich -- Senior Vice President

  Mark Baker -- Chief Executive Officer, Director

  Jim Garrison -- Head of Business Development and Commercial Strategy

  Robert Israel -- Senior Vice President - Medical Affairs & Clinical Research

  Paul Maddon -- Vice Chairman of the Board

  William Olson -- Senior Vice President - Research & Development

  Vivien Wong -- Vice President - Product Development

  Hagop Youssoufian -- Executive Vice President - Research & Development

Location Information

777 Old Sawmill River Road
Tarrytown, NY 10591
   (914) 789-2800
   www.progenics.com

Public Profile

Progenics Pharmaceuticals is a biopharmaceutical company focusing on the development and commercialization of innovative products for the treatment and prevention of cancer, viral and other life-threatening diseases. The Company applies its immunology expertise to develop biopharmaceuticals that induce an immune response or that mimic natural immunity in order to fight cancers, such as malignant melanoma, and viral diseases, such as human immunodeficiency virus (HIV) infection. The Company's product candidates include GMK, a therapeutic vaccine for the treatment of melanoma; MGV, a vaccine for the treatment of various cancers; and PRO-542 and PRO-367, which are therapeutic products designed to block HIV. Drug candidate PRO 140 is designed to prevent HIV from infecting healthy immune systems cells. The biotech's lead drug candidate, however, targets pain: Methylnatrexone (MNTX) could block the side effects of opioids without lessening their pain-killing power. Progenics is developing the drug in collaboration with Wyeth Pharmaceuticals. Also in the firm's pipeline is a vaccine that may prevent melanoma. Through subsidiary PSMA Development Company, Progenics is developing monoclonal antibodies and immuno-vaccines for prostate cancer.

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Headquartered
USA
Employment
62
Revenue
$0.0B
Public/Private
Publicly Traded
Stock Info
NASDAQ : PGNX
Received SBIR $$
Yes

SBIR firms in the news

There are no news available.